Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-01-25
2005-01-25
Wax, Robert A. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S411000, C540S469000, C530S317000
Reexamination Certificate
active
06846802
ABSTRACT:
The present invention discloses novel macrocyclic compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such macrocycles as well as methods of using them to treat disorders associated with the HCV protease.
REFERENCES:
patent: 5712145 (1998-01-01), Houghton et al.
patent: 381 216 (1990-08-01), None
patent: WO 8904669 (1989-06-01), None
patent: WO 9817679 (1998-04-01), None
patent: WO 9822496 (1998-05-01), None
patent: WO 9907734 (1999-02-01), None
patent: WO 99 07734 (1999-02-01), None
patent: WO0005245 (2000-02-01), None
patent: WO 0009543 (2000-02-01), None
patent: WO 0009558 (2000-02-01), None
patent: WO 00 09558 (2000-02-01), None
Pizzi, (1994)Proc. Natl. Acad. Sci(USA) 91:888-892.
Failla (1996)Folding&Design, 1:35-42.
Kollykhalov(1994)J. Virol., 68:7525-7533.
Komoda(1994)J. Virol. 68:7351-7357.
Landro (1997)Biochem. 36:9340-9348.
Ingallinella (1998)Biochem. 37:8906-8914.
Llinas-Brunet(1998)Bioorg. Med. Chem. Lett. 8:1713-1718.
Martin (1998)Biochem. 37:37:11459-11468.
Dimasi(1997)J. Virol. 71:7461-7469.
Martin(1997)Protein Eng. 10:607-614.
Elzoukl(1997)J. Hepat. 27:42-48.
BioWorld Today9(217): 4(Nov. 10, 1998).
Berenguer(1998)Proc. Assoc. Am. Physicians, 110(2):98-112.
Hoofnagle(1997)New England Journal of Medicine336:347.
Zhang (1999)Analytical Biochemistry270:268-275.
Sali(1998)Biochemistry37:3392-3401.
Barlos (1991)Int. J. Pept. Protein Res. 37:513-520.
Holmberg(1979)Acta Chem. ScandB33:410-412.
Agrawal(1999)HepatologySupplement to vol. 30“Development and Characterization of Hepatitis C Virus Serine Protease Cell-based Trans-Cleavage Assay”.
Hughes (1992)Org. Reactions42:335.
Heck (1989)Org. Reactions27:345-390.
Arasappan Ashok
Chen Kevin X.
Ganguly Ashit
Girijavallabhan Viyyoor Moopil
Gu Haining
Kalyanaraman Palaiyur S.
Mondesi Robert B
Schering Corporation
Wax Robert A.
LandOfFree
Macrocyclic NS3-serine protease inhibitors of hepatitis C... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Macrocyclic NS3-serine protease inhibitors of hepatitis C..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrocyclic NS3-serine protease inhibitors of hepatitis C... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3397603